<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002181'>Brain edema</z:hpo> formation is one of the most important mechanisms responsible for brain damage after <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Despite considerable efforts, no specific therapy is available yet </plain></SENT>
<SENT sid="2" pm="."><plain>Arginine vasopressin (AVP) regulates cerebral water homeostasis and has been involved in <z:hpo ids='HP_0002181'>brain edema</z:hpo> formation </plain></SENT>
<SENT sid="3" pm="."><plain>In the current study, we investigated the role of AVP V1 and V2 receptors on brain damage, <z:hpo ids='HP_0002181'>brain edema</z:hpo> formation, and functional outcome after transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, a condition comparable with that of <z:hpo ids='HP_0001297'>stroke</z:hpo> patients undergoing thrombolysis </plain></SENT>
<SENT sid="4" pm="."><plain>C57/BL6 mice were subjected to 60-min middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) followed by 23 h of reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>Five minutes after MCAO, 100 or 500 ng of [deamino-Pen(1), O-Me-Tyr(2), Arg(8)]-vasopressin (AVP V1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>) or [adamantaneacetyl(1), O-Et<z:chebi fb="0" ids="32781">-D-Tyr</z:chebi>(2), Val(4), Abu(6), Arg(8,9)]-vasopressin (AVP V2 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>) were injected into the left ventricle </plain></SENT>
<SENT sid="6" pm="."><plain>Inhibition of AVP V1 receptors reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in a dose-dependent manner by 54% and 70% (to 29+/-13 and 19+/-10 mm3 versus 63+/-17 mm3 in controls; P&lt;0.001), <z:hpo ids='HP_0002181'>brain edema</z:hpo> formation by 67% (to 80.4%+/-1.0% versus 82.7%+/-1.2% in controls; P&lt;0.001), blood-brain barrier disruption by 75% (P&lt;0.001), and functional deficits 24 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, while V2 receptor inhibition had no effect </plain></SENT>
<SENT sid="7" pm="."><plain>The current findings indicate that AVP V1 but not V2 receptors are involved in the pathophysiology of secondary brain damage after focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Although further studies are needed to clarify the mechanisms of neuroprotection, AVP V1 receptors seem to be promising targets for the treatment of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
</text></document>